Beam Therapeutics Appoints New Director, Discloses Officer Compensation
Ticker: BEAM · Form: 8-K · Filed: Dec 4, 2024
Sentiment: neutral
Topics: board-appointment, executive-compensation
Related Tickers: BEAM
TL;DR
Beam Therapeutics adds a new board member, David R. Walt, and updates on exec pay.
AI Summary
Beam Therapeutics Inc. announced on December 2, 2024, a change in its board of directors. Dr. David R. Walt has been appointed as a new director, effective immediately. The company also disclosed compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition can signal strategic shifts or governance updates, while compensation disclosures are important for understanding executive incentives and company spending.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and compensation disclosures, which are routine corporate events with no immediate negative financial implications.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Registrant
- Dr. David R. Walt (person) — Newly appointed director
- December 2, 2024 (date) — Effective date of appointment
FAQ
Who is the new director appointed to Beam Therapeutics' board?
Dr. David R. Walt has been appointed as a new director.
When was the appointment of the new director effective?
The appointment was effective as of December 2, 2024.
What other information did Beam Therapeutics disclose in this filing?
The company also disclosed compensatory arrangements of certain officers.
What is the state of incorporation for Beam Therapeutics Inc.?
Beam Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Beam Therapeutics Inc.?
The principal executive offices are located at 238 Main Street, Cambridge, Massachusetts, 02142.
Filing Stats: 705 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-12-04 07:08:52
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select
Filing Documents
- d912801d8k.htm (8-K) — 26KB
- d912801dex991.htm (EX-99.1) — 9KB
- g912801g1204030115937.jpg (GRAPHIC) — 3KB
- 0001193125-24-270314.txt ( ) — 159KB
- beam-20241202.xsd (EX-101.SCH) — 3KB
- beam-20241202_lab.xml (EX-101.LAB) — 17KB
- beam-20241202_pre.xml (EX-101.PRE) — 11KB
- d912801d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2024 Beam Therapeutics Inc. By: /s/ John Evans Name: John Evans Title: Chief Executive Officer